Wednesday, October 25, 2017 9:19:06 AM
MacroGenics skyrockets after Incyte deal
MacroGenics ($MGNX) skyrockets in premarket trading after the company inks a licensing deal with Incyte ($INCY) covering its MGA012 antibody.
Under the terms of the arrangement, Incyte pays MacroGenics an upfront payment of $150M and lands global development rights for MGA012.
Shares of MGNX are up 35% premarket to $21.80.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM